UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Completed
Unique ID issued by UMIN UMIN000031686
Receipt No. R000036188
Scientific Title The effects of peroral administration of Tofogliflozin(SGLT2 inhibitor) on endogenous glucose production and insulin clearance, single effet and chronic effect.
Date of disclosure of the study information 2018/03/16
Last modified on 2019/06/13

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title The effects of peroral administration of Tofogliflozin(SGLT2 inhibitor) on endogenous glucose production and insulin clearance, single effet and chronic effect.
Acronym The effect of Tofogliflozin(SGLT2 inhibitor) on endogenous glucose production and insulin clearance
Scientific Title The effects of peroral administration of Tofogliflozin(SGLT2 inhibitor) on endogenous glucose production and insulin clearance, single effet and chronic effect.
Scientific Title:Acronym The effect of Tofogliflozin(SGLT2 inhibitor) on endogenous glucose production and insulin clearance
Region
Japan

Condition
Condition Type 2 diabetes mellitus
Classification by specialty
Medicine in general Endocrinology and Metabolism
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To examine the effects of peroral administration of Tofogliflozin(SGLT2 inhibitor) on endogenous glucose production and insulin clearance, a single effect and chronic effect.
Basic objectives2 Pharmacokinetics
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes To examine the effects of peroral administration of Tofogliflozin(SGLT2 inhibitor) on endogenous glucose production and insulin clearance, a single effect and chronic effect.
Key secondary outcomes After administration of Tofogliflozin
-Intrahepatic lipid
-Intramyocellular lipid
-Visceral fat area
-Subcutaneous fat area
-Body weight, Body composition
-Endogenous glucose production
-Insulin sensitivity
-Metabolic flexibility
-Metabolome analysis

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Self control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 take Tofogliflozin orally
One day and 8 weeks
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
40 years-old <=
Age-upper limit
65 years-old >=
Gender Male
Key inclusion criteria -type 2 diabetes mellitus men
-BMI range: 18.5-30 kg/m2
-HbA1c range:7.5-10.0%
-The patient who did not being changed the way to take diabetes medicines(additional dosage, discontinulation of administration or changing dosage) within 12 weeks before agreement acquisition
-Persons who gained document consent by the patient's free intention after having sufficient explanation for participation in this study and having sufficient understanding
Key exclusion criteria -type 1 diabetes mellitus
-past history of taking Tofogliflozin
-BMI range:>30 or <18.5 kg/m2
-liver dysfunction(AST,ALT => 51U/L,gamma-GTP over 101U/L)
-renal dysfunction or eGFR level =< 60mL/min/1.73m2
-Patient with severe heart diseases (for example, heart failure and unstable angina) or the patient who occured myocardial infarction and anginal attack after 24 weeks ago from observation period
-patient who had an apoplexy spasm (cerebral infarction and cerebral hemorrhage) within 24 weeks until agreement acquisition
-patient with malignant tumor
-patient with advanced diabetes complications (neuropathy , retinopathy and nephropathy)
-patient of serious illness ketotic, a diabetic coma or the previous coma
-Patient with the endocrine diseases for which treatment is insufficient for hormone replenishment method of treatment (for example,pituitary disease, thyroid disease and adrenal disease)
-anemia beyond the degree of middle class (hemoglobin < 9.5g/dL)
-drunkard(for example 1 daily mean sake, by 3 gou and beer, more than 3 flagons)
-subjects judged unsuitable to the study from staff
Target sample size 12

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Yoshifumi Tamura
Organization University of Juntendo
Division name Department of Endocrinology & Metabolism,Sportology center, Faculty of International Liberal Arts. Area of Global Health service
Zip code
Address 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421 JAPAN
TEL 03-3837-0618
Email hkaga@juntendo.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Hideyoshi Kaga
Organization University of Juntendo
Division name Department of Endocrinology and Metabolism, Sportology Center
Zip code
Address 2-1-1, Hongo, Bunkyo-ku, Tokyo 113-8421 JAPAN
TEL 03-3887-0618
Homepage URL
Email hkaga@juntendo.ac.jp

Sponsor
Institute University of Juntendo
Institute
Department

Funding Source
Organization University of Juntendo
Organization
Division
Category of Funding Organization Japanese Governmental office
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2018 Year 03 Month 16 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Completed
Date of protocol fixation
2017 Year 11 Month 15 Day
Date of IRB
2017 Year 11 Month 15 Day
Anticipated trial start date
2018 Year 04 Month 01 Day
Last follow-up date
2019 Year 02 Month 12 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2018 Year 03 Month 12 Day
Last modified on
2019 Year 06 Month 13 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036188

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.